A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic

Investigator(s):
Bartosz Chmielowski, M.D.;
Organization: 
UCLA
NCT Number: 
Disease Name: 
Solid Tumor
Disease Category: 
Trial Phases: 
Phase 1
Trial Status: 
Not Yet Recruiting
Trial Contact: 

Louis A. Sloniker
(310) 794-6993
LSloniker@mednet.ucla.edu